Cargando…
Recent Advances in Manufacturing Innovative Stents
Cardiovascular diseases are the most distributed cause of death worldwide. Stenting of arteries as a percutaneous transluminal angioplasty procedure became a promising minimally invasive therapy based on re-opening narrowed arteries by stent insertion. In order to improve and optimize this method, m...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238261/ https://www.ncbi.nlm.nih.gov/pubmed/32294908 http://dx.doi.org/10.3390/pharmaceutics12040349 |
_version_ | 1783536505354977280 |
---|---|
author | Beshchasna, Natalia Saqib, Muhammad Kraskiewicz, Honorata Wasyluk, Łukasz Kuzmin, Oleg Duta, Oana Cristina Ficai, Denisa Ghizdavet, Zeno Marin, Alexandru Ficai, Anton Sun, Zhilei Pichugin, Vladimir F. Opitz, Joerg Andronescu, Ecaterina |
author_facet | Beshchasna, Natalia Saqib, Muhammad Kraskiewicz, Honorata Wasyluk, Łukasz Kuzmin, Oleg Duta, Oana Cristina Ficai, Denisa Ghizdavet, Zeno Marin, Alexandru Ficai, Anton Sun, Zhilei Pichugin, Vladimir F. Opitz, Joerg Andronescu, Ecaterina |
author_sort | Beshchasna, Natalia |
collection | PubMed |
description | Cardiovascular diseases are the most distributed cause of death worldwide. Stenting of arteries as a percutaneous transluminal angioplasty procedure became a promising minimally invasive therapy based on re-opening narrowed arteries by stent insertion. In order to improve and optimize this method, many research groups are focusing on designing new or improving existent stents. Since the beginning of the stent development in 1986, starting with bare-metal stents (BMS), these devices have been continuously enhanced by applying new materials, developing stent coatings based on inorganic and organic compounds including drugs, nanoparticles or biological components such as genes and cells, as well as adapting stent designs with different fabrication technologies. Drug eluting stents (DES) have been developed to overcome the main shortcomings of BMS or coated stents. Coatings are mainly applied to control biocompatibility, degradation rate, protein adsorption, and allow adequate endothelialization in order to ensure better clinical outcome of BMS, reducing restenosis and thrombosis. As coating materials (i) organic polymers: polyurethanes, poly(ε-caprolactone), styrene-b-isobutylene-b-styrene, polyhydroxybutyrates, poly(lactide-co-glycolide), and phosphoryl choline; (ii) biological components: vascular endothelial growth factor (VEGF) and anti-CD34 antibody and (iii) inorganic coatings: noble metals, wide class of oxides, nitrides, silicide and carbide, hydroxyapatite, diamond-like carbon, and others are used. DES were developed to reduce the tissue hyperplasia and in-stent restenosis utilizing antiproliferative substances like paclitaxel, limus (siro-, zotaro-, evero-, bio-, amphi-, tacro-limus), ABT-578, tyrphostin AGL-2043, genes, etc. The innovative solutions aim at overcoming the main limitations of the stent technology, such as in-stent restenosis and stent thrombosis, while maintaining the prime requirements on biocompatibility, biodegradability, and mechanical behavior. This paper provides an overview of the existing stent types, their functionality, materials, and manufacturing conditions demonstrating the still huge potential for the development of promising stent solutions. |
format | Online Article Text |
id | pubmed-7238261 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72382612020-06-02 Recent Advances in Manufacturing Innovative Stents Beshchasna, Natalia Saqib, Muhammad Kraskiewicz, Honorata Wasyluk, Łukasz Kuzmin, Oleg Duta, Oana Cristina Ficai, Denisa Ghizdavet, Zeno Marin, Alexandru Ficai, Anton Sun, Zhilei Pichugin, Vladimir F. Opitz, Joerg Andronescu, Ecaterina Pharmaceutics Review Cardiovascular diseases are the most distributed cause of death worldwide. Stenting of arteries as a percutaneous transluminal angioplasty procedure became a promising minimally invasive therapy based on re-opening narrowed arteries by stent insertion. In order to improve and optimize this method, many research groups are focusing on designing new or improving existent stents. Since the beginning of the stent development in 1986, starting with bare-metal stents (BMS), these devices have been continuously enhanced by applying new materials, developing stent coatings based on inorganic and organic compounds including drugs, nanoparticles or biological components such as genes and cells, as well as adapting stent designs with different fabrication technologies. Drug eluting stents (DES) have been developed to overcome the main shortcomings of BMS or coated stents. Coatings are mainly applied to control biocompatibility, degradation rate, protein adsorption, and allow adequate endothelialization in order to ensure better clinical outcome of BMS, reducing restenosis and thrombosis. As coating materials (i) organic polymers: polyurethanes, poly(ε-caprolactone), styrene-b-isobutylene-b-styrene, polyhydroxybutyrates, poly(lactide-co-glycolide), and phosphoryl choline; (ii) biological components: vascular endothelial growth factor (VEGF) and anti-CD34 antibody and (iii) inorganic coatings: noble metals, wide class of oxides, nitrides, silicide and carbide, hydroxyapatite, diamond-like carbon, and others are used. DES were developed to reduce the tissue hyperplasia and in-stent restenosis utilizing antiproliferative substances like paclitaxel, limus (siro-, zotaro-, evero-, bio-, amphi-, tacro-limus), ABT-578, tyrphostin AGL-2043, genes, etc. The innovative solutions aim at overcoming the main limitations of the stent technology, such as in-stent restenosis and stent thrombosis, while maintaining the prime requirements on biocompatibility, biodegradability, and mechanical behavior. This paper provides an overview of the existing stent types, their functionality, materials, and manufacturing conditions demonstrating the still huge potential for the development of promising stent solutions. MDPI 2020-04-13 /pmc/articles/PMC7238261/ /pubmed/32294908 http://dx.doi.org/10.3390/pharmaceutics12040349 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Beshchasna, Natalia Saqib, Muhammad Kraskiewicz, Honorata Wasyluk, Łukasz Kuzmin, Oleg Duta, Oana Cristina Ficai, Denisa Ghizdavet, Zeno Marin, Alexandru Ficai, Anton Sun, Zhilei Pichugin, Vladimir F. Opitz, Joerg Andronescu, Ecaterina Recent Advances in Manufacturing Innovative Stents |
title | Recent Advances in Manufacturing Innovative Stents |
title_full | Recent Advances in Manufacturing Innovative Stents |
title_fullStr | Recent Advances in Manufacturing Innovative Stents |
title_full_unstemmed | Recent Advances in Manufacturing Innovative Stents |
title_short | Recent Advances in Manufacturing Innovative Stents |
title_sort | recent advances in manufacturing innovative stents |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238261/ https://www.ncbi.nlm.nih.gov/pubmed/32294908 http://dx.doi.org/10.3390/pharmaceutics12040349 |
work_keys_str_mv | AT beshchasnanatalia recentadvancesinmanufacturinginnovativestents AT saqibmuhammad recentadvancesinmanufacturinginnovativestents AT kraskiewiczhonorata recentadvancesinmanufacturinginnovativestents AT wasylukłukasz recentadvancesinmanufacturinginnovativestents AT kuzminoleg recentadvancesinmanufacturinginnovativestents AT dutaoanacristina recentadvancesinmanufacturinginnovativestents AT ficaidenisa recentadvancesinmanufacturinginnovativestents AT ghizdavetzeno recentadvancesinmanufacturinginnovativestents AT marinalexandru recentadvancesinmanufacturinginnovativestents AT ficaianton recentadvancesinmanufacturinginnovativestents AT sunzhilei recentadvancesinmanufacturinginnovativestents AT pichuginvladimirf recentadvancesinmanufacturinginnovativestents AT opitzjoerg recentadvancesinmanufacturinginnovativestents AT andronescuecaterina recentadvancesinmanufacturinginnovativestents |